Codexis, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2022 and for the Full Year 2022
July 14, 2022 at 04:05 pm EDT
Share
Codexis, Inc. provided revenue guidance for the second quarter ending June 30, 2022 and for the full year 2022. The company currently expects total revenues for the second quarter of 2022 to be approximately $38 million.
Total revenues for full year 2022 are expected to be in the range of $135 million to $141 million.
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
CODEXIS, INC. 
